# Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

> **NCT01558869** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 37 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01558869
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01558869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01558869, "Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01558869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*